✦ LIBER ✦

Phase II trial of rhIL-6 (Interleukin-6) prior to and concurrently with VAD (vincristine, doxorubicin and dexamethasone) chemotherapy for patients with multiple myeloma

✍ Scribed by R.I. Young; M. Ranson; J. Chang; B. Lord; N. Testa; J.H. Scarffe

Book ID: 117663638
Publisher: Elsevier Science
Year: 1997
Tongue: English
Weight: 584 KB
Volume: 33
Category: Article
ISSN: 0959-8049
DOI: 10.1016/s0959-8049(96)00383-8

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Phase III study of PSC-833 (valspodar) i

Phase III study of PSC-833 (valspodar) in combination with vincristine, doxorubicin, and dexamethasone (valspodar/VAD) versus VAD alone in patients with recurring or refractory multiple myeloma (E1A95) : A trial of the Eastern Cooperative Oncology Group

✍ William R. Friedenberg; Montserrat Rue; Emily A. Blood; William S. Dalton; Chaim 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 149 KB 👁 1 views

Sequential vincristine, adriamycin, dexa

Sequential vincristine, adriamycin, dexamethasone (VAD) followed by bortezomib, thalidomide, dexamethasone (VTD) as induction, followed by high-dose therapy with autologous stem cell transplant and consolidation therapy with bortezomib for newly diagnosed multiple myeloma: results of a phase II trial

✍ Hye Jin Kim; Sung-Soo Yoon; Dong Soon Lee; Sang Kyun Sohn; Hyeon Seok Eom; Jung 📂 Article 📅 2011 🏛 Springer 🌐 English ⚖ 184 KB